Alpharadin

The drug, Radium-223 Chloride - known as Alpharadin TM - will also do less damage to surrounding tissue because it accurately targets calls, the doctors said.

Telegraph.co.uk - Telegraph online, Daily Telegraph and Sunday Telegraph Edward Malnick 2011

Germany's Bayer rose 1.5% after it said a Phase III trial for Alpharadin on patients with prostate cancer met the primary endpoint of significantly improving overall survival.

Greek Worries Sink European Stocks Simon Kennedy 2011

In September 2009, Bayer signed an agreement with Algeta to develop and commercialize Alpharadin, also known as radium-223 chloride, a compound containing an alpha-particle-emitting nuclide for cancer patients with bone metastases.

Bayer Prostate Drug Gets a Boost Sten Stovall 2011

Encouraging studies on Alpharadin and two other potential blockbuster drugs—eye-disease treatment Eylea or VEGF Trap-Eye and blood thinner Xarelto—have recently fanned enthusiasm for Bayer's pharmaceutical business.

Bayer Prostate Drug Gets a Boost Sten Stovall 2011

News that Alpharadin won FDA fast-track status—which accelerates a drug's approval process by around six months—reminded investors of Bayer's promising drug pipeline and generated strong demand for Bayer shares, sending them up more than 3% in morning business.

Bayer Prostate Drug Gets a Boost Sten Stovall 2011

The analysis showed median survival was 14 months for those on Alpharadin, compared with 11.2 months for those on placebo, according to Bayer.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011

Next to blood thinner Xarelto, two other drug potential blockbuster medicines - eye disease treatment Eylea or prostate cancer drug Alpharadin—have captured analyst focus lately, casting a more optimistic light on the pharma business as a whole.

Bayer Delivers a Mixed Bag Natascha Divac 2011

Alpharadin, or radium-223 chloride, specifically targets cancer that has spread to the bone.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011

Bayer's pipeline got a boost after a trial of its experimental drug Alpharadin was cut short early to allow patients receiving placebo to be offered the new medicine.

What's News— 2011

Bayer's Alpharadin, which emits alpha radiation, would be the fourth new drug since early last year to reach the market for advanced prostate cancer, a lethal condition for which few effective treatments previously existed.

Bayer Drug Shows Promise in Treating Prostate Cancer Ron Winslow 2011